The Hidden Role of Radiation Safety in Clinical Trial Activation
Radiopharmaceutical trials are often delayed long before patient recruitment begins. Protocols are drafted. Sites are identified. Timelines are set.
But activation still stalls.
One of the most consistent and least visible contributors to these delays is radiation safety.
In radiopharmaceutical trials, radiation safety is not just a compliance function. It is often a gating step that directly affects when a study can move from planning to execution. At many institutions, radiation safety review must occur before or alongside institutional review board approval, shaping when a trial can begin [1].
Radiation Safety Is Not a Final Step
In many development plans, radiation safety is treated as something to address near the end of site startup.
In practice, it must be addressed much earlier.
Before a study can begin, sites must define how radioactive material will be received, handled, administered, stored, and disposed. Teams must evaluate exposure risks, confirm shielding and storage requirements, and align workflows with institutional and regulatory standards.
These steps are foundational. They determine whether a site can safely and consistently execute the protocol.
The Timing Problem Sponsors Often Underestimate
The challenge is not only the requirement for radiation safety review. It is the timing and coordination that surround it.
Radiopharmaceutical startup spans multiple groups, including clinical research, nuclear medicine, pharmacy, radiation safety, imaging, and environmental health and safety. Each group operates with its own timelines and review structure.
At many institutions, radiation safety review is conducted through committees that meet on fixed schedules. Submissions must be complete before review. If revisions are needed, the process may move to the next cycle.
What appears to be a single approval step becomes a multi-stage process with dependencies.
Delays rarely come from one issue. They accumulate through sequencing, revisions, and handoffs across teams.
Why Experience Does Not Eliminate the Risk
Sites with prior radiopharmaceutical experience are often expected to activate more quickly.
They are usually better prepared. But that does not remove the need for review.
Each study introduces variables that must be reassessed. These may include different radionuclides, new activity levels, updated imaging requirements, or changes in handling and waste procedures.
Even small differences can trigger new evaluations.
Institutional policies also require alignment between protocol requirements, approved workflows, facilities, and personnel. Prior experience helps reduce uncertainty, but it does not eliminate friction or the need for reapproval [2].
Radiation Safety Is Also an Operational Constraint
Radiation safety is not only a review process. It is an operational constraint that reflects the realities of site infrastructure and coordination.
Radiopharmaceutical trials require appropriate space to receive and store materials, prepare doses, and manage patient administration. Sites must ensure proper shielding, monitoring, and separation from other clinical activities.
These requirements directly affect whether a site can support a study.
Implementation frameworks for radioligand therapy programs highlight the need for dedicated infrastructure and coordinated workflows across teams. They also point to the time and effort required from both clinical and radiation safety staff to support these programs [3][4].
This is often where gaps become visible. A site may appear capable on paper, but still lack the infrastructure or coordination needed to move efficiently.
A Growing Constraint as Trials Become More Complex
The role of radiation safety is expanding as radiopharmaceutical trials become more complex.
Many studies now include multiple imaging timepoints, dosimetry assessments, and a stronger focus on dose optimization and patient-specific exposure. FDA guidance reflects this shift by emphasizing the importance of understanding dose and exposure during development [5].
Regulatory expectations are also evolving globally. The European Medicines Agency has highlighted the need for more defined approaches to evaluating therapeutic radiopharmaceuticals in oncology [6].
As complexity increases, so does the burden on radiation safety teams.
Sites that are not structured to support this level of coordination will face longer review cycles and slower activation timelines.
Theragnostic Insight - Radiation safety becomes a bottleneck when it is treated as a late step instead of an integrated part of trial design and site strategy.
What This Means for Sponsors
For sponsors, the implication is clear.
Radiation safety must be integrated into early planning, not treated as a final checkpoint.
The most useful questions are operational:
• How does radiation safety review work at this site
• What documentation is required and when
• How often do review committees meet
• What facility or staffing constraints could affect approval
• Where have delays occurred in prior studies
Without this level of insight, activation timelines are often underestimated.
What This Means for You
Radiopharmaceutical development depends on more than a strong protocol. It depends on whether a site can translate that protocol into a safe and executable process.
Radiation safety plays a central role in that translation.
At Theragnostic Insights, we help development teams evaluate these realities early, aligning protocol requirements with site workflows, infrastructure, and regulatory processes.
Because in radiopharmaceutical development, delays are rarely driven by one major issue.
They are driven by multiple small steps that were not aligned from the start.
Stay tuned for more in this mini-series: Clinical Capacity Crisis: The Hidden Bottleneck in Radiopharma Development.
In the coming weeks, we’ll continue exploring the clinical capacity crisis holding back radiopharmaceutical innovation; from regional access gaps to operational gridlock and infrastructure blind spots. Don’t miss the next post as we map out the road to a truly trial-capable ecosystem.
1. The Trial Site Gap: Why Radiopharmaceutical Innovation Is Hitting a Wall
2. Geography Is Destiny: The Clinical Access Gaps in Radiopharmaceutical Research
3. Operational Gridlock: Where Radiopharmaceutical Trials Break Down on Site
4. Beyond the Badge: Rethinking What “Trial-Ready” Really Means in Radiopharma
5. Infrastructure as Investment Strategy: Clinical Site Access and Radiopharma ROI
6. Built for What’s Next: Redefining Clinical Site Design for Theragnostic Trials
7. Speed as Strategy: How Site Scarcity Is Slowing Radiopharmaceutical Pipelines
8. One Roof, Many Bottlenecks: Why Fragmented Site Models Undermine RLT Trials
9. The Dosimetry Dilemma: Why Many Sites Aren’tReady for Radioligand Trials
10. Licensing & Radiation Safety: The Regulatory Maze Behind Radiopharmaceutical Trials
11. The Hidden Role of Radiation Safety in Clinical Trial Activation
References:
[1] Johns Hopkins Medicine, 2025. 103.21 Organization Policy on Clinical Radiation Research Committee and Radioactive Drug Research Committee Review for Human Subject Research. Johns Hopkins Medicine.
[2] University of Pittsburgh Radiation Safety Office, 2025. Human Use Radiopharmaceutical Clinical Trials Procedure and Policy. University of Pittsburgh.
[3] Hope et al., 2024. Establishing a robust radioligand therapy program: A practical approach and framework from a North American perspective. PMC.
[4] European Society of Medicine, 2025. Optimizing Radiopharmaceutical Therapy in Clinical Trials. European Society of Medicine.
[5] U.S. Food and Drug Administration, 2025. Oncology Therapeutic Radiopharmaceuticals: Dosage Optimization During Clinical Development. U.S. Food and Drug Administration.
[6] European Medicines Agency, 2024. Concept paper on the clinical evaluation of therapeutic radiopharmaceuticals in oncology. European Medicines Agency.
